X

Drug Profile

NCX 2216

Latest Information Update: 16 May 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NicOx
Class Antidementias; Neuroprotectants; Nonsteroidal anti-inflammatories; Propionic acids; Small molecules
Mechanism of Action Antioxidants; Nitric oxide donors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Alzheimer's disease

Most Recent Events

01 Sep 2004 A preclinical study has been added to the pharmacodynamics section
23 Jul 2004 Data presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2004) have been added to Pharmacodynamics section
17 Oct 2002 This compound is still in active development

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com